Modular Medical

MODD

Market cap $16.5M

SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced the pricing of a public offering with new and existing investors of 68,098,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 68,098,000 shares of its common stock at a combined public offering price of $0.1762 per share (or pre-funded warrant) and accompanying warrant. The warrants will have an exercise price of $0.1762 per share, will be exercisable immediately, and will expire five years from the date of issuance.

Targeting Q1 2026 Launch, Subject to FDA Clearance Key Highlights: Cartridge & Infusion Set Lots in Production: Validation production lots now being produced for launch, derisking commercial-scale production. First Removable Tubeless Patch Pump: Pivot targets underserved "almost-pumpers" - adults with diabetes hesitant to move from multiple daily injections (MDI) due to cost and complexity - representing a significant portion of the growing ~$8 billion global insulin pump market.

SAN DIEGO, CA / ACCESS Newswire / December 31, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced the Company received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5810(c)(3)(A) (the "Bid Price Rule"). The Company now has until June 29, 2026 to meet the requirement.

SAN DIEGO, CA / ACCESS Newswire / December 10, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has priced an underwritten public offering (the "offering") of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant.

SAN DIEGO, CA / ACCESS Newswire / December 9, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock and warrants to purchase shares of its common stock. The shares of the common stock and the accompanying warrants are immediately separable and will be issued separately but can only be purchased together in this offering.

Study to Deliver Insulin to Internal Testers Wearing Continuous Glucose Monitors SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the $3 billion adult "almost-pumpers" diabetes market with user-friendly, affordable patch pumps, today announced Institutional Review Board ("IRB") approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the "Study"). Pursuant to U.S. Food and Drug Administration ("FDA") regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects.

-Targets $3 Billion "Almost-Pumper" Market with First Simplified and Removable/Replaceable Insulin Patch Pump - Aims to Improve Patient and Clinician Experience for the Care of Diabetes SAN DIEGO, CA / ACCESS Newswire / November 14, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company") today announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the "FDA"). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026.

Key Highlights: Pivot Controller Line Validated: Manufacturing line has now been validated for human-use production in support of expected Q1 2026 market launch. Pivot will be First Two-Part Tubeless Patch Pump: Pivot, a 3 milliliter removable patch pump, targets the $3 billion dollar market for adult "almost-pumpers" with its affordable, user-friendly, easy-to-learn design.

Key Highlights: Pivot continues to progress toward CE Mark certification in 2026 Stage 1 ISO Audit completed with Stage 2 planned for 1H2026 SAN DIEGO, CA / ACCESS Newswire / October 28, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery, today announced that it is continuing to progress toward CE Mark certification under the European Union Medical Device Regulation ("EU MDR 2017/745"). As part of this process, the Company is pleased to announce the successful completion of its Stage 1 ISO 13485:2016 audit, conducted by BSI, its Notified Body and Registrar.

-Seasoned Executive with Proven Track Record in International Pump Launches to Accelerate Global Adoption of User Friendly, Affordable Patch Pumps SAN DIEGO, CA / ACCESS Newswire / October 6, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the $3 billion adult "almost-pumpers" diabetes market with easy to learn and operate user-friendly, affordable patch pumps, today announced the appointment of David Bosshard as Head of International Operations. With two decades of expertise in scaling similar tubeless insulin delivery systems across Europe and beyond, Mr.